Gastric Cancer

, Volume 22, Issue 5, pp 988–998 | Cite as

Hypoalbuminemia for the prediction of venous thromboembolism and treatment of direct oral anticoagulants in metastatic gastric cancer patients

  • Kotoe Takayoshi
  • Hitoshi Kusaba
  • Tomomi Aikawa
  • Sakuya Koreishi
  • Kosuke Sagara
  • Michitaka Nakano
  • Masato Komoda
  • Mihoko Kono
  • Mitsuhiro Fukata
  • Takeshi Arita
  • Taito Esaki
  • Koichi Akashi
  • Eishi BabaEmail author
Original Article



Venous thromboembolism (VTE) is highly associated with advanced gastric cancer (AGC) and is sometimes lethal. Predictors of VTE have not been identified, and the efficacy and safety of direct oral anticoagulants (DOACs) for AGC-associated VTE remain to be clarified.


A total of 188 AGC patients who started chemotherapy during the period from January 2014 to December 2017 in our institutions were retrospectively examined for the incidence of VTE, risk factors for VTE, and the efficacy and safety of DOAC-based anticoagulant therapy for VTE.


Thirty-four patients (18%) were diagnosed with VTE at the start or during the course of chemotherapy (VTE group). More VTE group patients had a history of abdominal surgery and had moderate–severe ascites (32% versus 17%, 32% versus 14%, respectively) than non-VTE group patients (NVTE group). The mean serum albumin concentrations in the VTE group were significantly lower than NVTE group (3.38 mg/dL vs 3.65 mg/dL, respectively). Multivariate analysis showed that hypoalbuminemia was significantly correlated with VTE (P = 0.012). In the VTE group, 29 patients (85%) received anticoagulant therapy, including 24 patients treated with DOACs. No lethal VTE was observed in any patients. Thirteen patients (45%) terminated DOACs because of anemia or bleeding events, of whom eleven developed major bleeding. Median overall survivals of the VTE and NVTE groups were 9.63 months and 11.5 months, respectively (P = 0.262).


Hypoalbuminemia appears to be a risk factor for AGC-associated VTE. DOACs are effective to AGC-associated VTE, but careful observation of bleeding events is required.


Venous thromboembolism Gastric cancer Hypoalbuminemia Direct oral anticoagulants Bleeding 


Compliance with ethical standards

Conflict of interest

M. Kono has received grants from Pfizer Japan Inc. M. Fukata has received grants from Shino-Test Corporation; personal fees from Pfizer, Daiichi Sankyo Company, Bayer Yakuhin, and Boehringer Ingelheim. T. Esaki has received grants and personal fees from Eli Lilly, Taiho, Daiichi-Sankyo, Merck Serono, and Ono; grants from Novartis, DS pharma, MSD and Boehringer; personal fees from Chugai, Bristol, Eisai and Takeda. K. Akashi has received grants and personal fees from Mitsubishi Tanabe Pharma Corporation, Daiichi-Sankyo, MSD, Eisai, Astellas Pharma, Sanofi, Chugai Pharmaceutical, Asahi Kasei Pharma, Kyowa Hakko Kirin, Sumitomo Dainippon Pharma, Bristol-Myers Squibb, Takeda Pharmaceutical, Novartis Pharma, Alexion Pharmaceuticals, Teijin Pharma, Nippon Shinyaku, Yakult Honsha, Mundipharma and Bayer Yakuhin; grants from Ono Pharmaceutical, Merck Serono, Toyama Chemical, Taiho Pharmaceutical, Otsuka Pharmaceutical, Yakult Honsha Co, AbbVie, Shionogi, Eli Lilly Japan, Taisho Toyama Pharmaceutical, Mochida Pharmaceutical, The Chemo-Sero-Therapeutic Research Institute., Merck Serono, Nippon Kayaku, Japan Blood Products Organization, and Shin Nippon Biomedical Laboratories; personal fees from Celgene, Janssen Pharmaceutical, Pfizer, Medical Review, Amgen Astellas Biopharma and Shire Japan. E. Baba has received grants, personal fees and non-financial support from Eli Lilly Japan; grants and personal fees from Daiichi-Sankyo, Bristol-Myers Squibb, Taiho Pharmaceutical. Eisai, Yakult Honsha, and Ono Pharmaceutical; grants from Bayer Yakuhin, MSD, Linical; personal fees from Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Kyowa Hakko Kirin, Sanofi, Merck Serono, Tsumura, Chugai Pharmaceutical, and Astellas Pharma. All of the remaining authors declare that they have no conflicts of interest.

Ethical standards

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consent or substitute for it was obtained from all patients for being included in the study.


  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. Scholar
  2. 2.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guideline 2018 (ver.5). Kanehara. 2018Google Scholar
  3. 3.
    Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefGoogle Scholar
  8. 8.
    Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401–10.CrossRefGoogle Scholar
  9. 9.
    Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, et al. Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience. Eur J Cancer. 2012;48:492–500.CrossRefGoogle Scholar
  10. 10.
    Park K, Ryoo BY, Ryu MH, Park SR, Kang MJ, Kim JH, et al. Incidence of venous thromboembolism and the role of d-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: a prospective study. World J Gastrointest Oncol. 2017;9:176–83.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Arai H, Hironaka S, Minashi K, Denda T, Shimokawa M, Yamaguchi T. Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer. Jpn J Clin Oncol. 2017;47:942–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Lee KW, Bang SM, Kim S, Lee HJ, Shin DY, Koh Y, et al. The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer. J Thromb Haemost. 2010;8:540–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–50.CrossRefPubMedGoogle Scholar
  15. 15.
    Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118:555–68.CrossRefPubMedGoogle Scholar
  16. 16.
    Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology Cancer-associated venous thromboembolic disease. Version 2. 2018.
  18. 18.
    Mandalà M, Falanga A, Roila F. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011. Scholar
  19. 19.
    Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ramos JD, Casey MF, Bamias A, De Giorgi U, Bellmunt J, Harshman LC, et al. The Khorana score in predicting venous thromboembolism for patients with metastatic urothelial carcinoma and variant histology treated with chemotherapy. Clin Appl Thromb Hemost. 2017;23:755–60.CrossRefPubMedGoogle Scholar
  21. 21.
    van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res. 2017;150:30–2.CrossRefPubMedGoogle Scholar
  22. 22.
    Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014. Scholar
  23. 23.
    Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–91.CrossRefGoogle Scholar
  24. 24.
    Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615–24.CrossRefPubMedGoogle Scholar
  25. 25.
    JCS joint working group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J. 2011;75:1258–81.CrossRefGoogle Scholar
  26. 26.
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–4.CrossRefPubMedGoogle Scholar
  27. 27.
    Diao D, Wang Z, Cheng Y, Zhang H, Guo Q, Song Y, et al. D-dimer: not just an indicator of venous thrombosis but a predictor of asymptomatic hematogenous metastasis in gastric cancer patients. PLoS One. 2014. Scholar
  28. 28.
    Stender MT, Larsen TB, Sorensen HT, Thorlacius-Ussing O. Preoperative plasma d-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study. J Thromb Haemost. 2012;10:2027–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High d-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97:1158–64.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Diao D, Cheng Y, Song Y, Zhang H, Zhou Z, Dang C. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer. BMC Cancer. 2017. Scholar
  31. 31.
    Königsbrügge O, Posch F, Riedl J, Reitter EM, Zielinski C, Pabinger I, et al. Association between decreased serum albumin with risk of venous thromboembolism and mortality in cancer patients. Oncologist. 2016;21:252–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP. Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies. J Thromb Haemost. 2010;8:1702–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Folsom AR, Lutsey PL, Heckbert SR, Cushman M. Serum albumin and risk of venous thromboembolism. Thromb Haemost. 2010;104:100–4.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrol Dial Transplant. 2017;32:157–64.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost. 2005;94:362–5.PubMedGoogle Scholar
  36. 36.
    Paar M, Rossmann C, Nusshold C, Wagner T, Schlagenhauf A, Leschnik B, et al. Anticoagulant action of low, physiologic, and high albumin levels in whole blood. PLoS One. 2017;12:e0182997. Scholar
  37. 37.
    Maclouf J, Kindahl H, Granström E, Samuelsson B. Interactions of prostaglandin H2 and thromboxane A2 with human serum albumin. Eur J Biochem. 1980;109:561–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599–610.CrossRefPubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2019

Authors and Affiliations

  • Kotoe Takayoshi
    • 1
  • Hitoshi Kusaba
    • 2
  • Tomomi Aikawa
    • 1
  • Sakuya Koreishi
    • 1
  • Kosuke Sagara
    • 1
  • Michitaka Nakano
    • 1
  • Masato Komoda
    • 1
  • Mihoko Kono
    • 3
  • Mitsuhiro Fukata
    • 2
  • Takeshi Arita
    • 2
  • Taito Esaki
    • 1
  • Koichi Akashi
    • 2
  • Eishi Baba
    • 4
    Email author
  1. 1.Department of Gastrointestinal and Medical OncologyNational Kyushu Cancer CenterFukuokaJapan
  2. 2.Department of Medicine and Biosystemic ScienceKyushu University Graduate School of Medical Sciences, Kyushu UniversityFukuokaJapan
  3. 3.Department of CardiologyNational Kyushu Cancer CenterFukuokaJapan
  4. 4.Department of Comprehensive Clinical Oncology, Faculty of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations